FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread. Patients must have received at least two prior therapies.
Read more: FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments